Saluda Medical Inc · ASX:SLD
Saluda Medical — Q1 FY2027 Earnings Presentation
13 slides from Saluda Medical's earnings presentation, Oct 29, 2026
Slide 1: Saluda Medical FY27 Q1 Update
rsonal use only Saluda Medical FY27 Q1 Update October 29, 2026 Weare on a Mission to Transform Patients’ Lives with Revolutionary Neural-Sensing Technology
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer THIS DOCUMENT AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIB
Slide 3: Saluda's Value Proposition
Saluda’s Value Proposition Clinical differentiation converging into commercial and economic leverage rsonal use only PAIN RELIEF AT 36 MONTHS Durability 83% Most compelling long-term efficacy profile in SCS Zero explants for loss of efficacy in EVOKE clinical trial REPROGRAMMING VISITS PER YEAR Over
Slide 4: Evoke System Stimulates, Measures and Adjusts Therapy on Every Pulse
Evoke® System Stimulates, Measures and Adjusts Therapy on Every Pulse Implanted lead delivers stimulation & measures resulting neural response, enabling personalised therapy rsonal use only Stimulate Individual optimal dose Patient A Pain relief starts with neural SCS activation leads Neural activat
Slide 5: Lower Reprogramming Rates | Real World Experience
Lower ReprogrammingRates | Real World Experience Commercial patients through June 2026 have less than one reprogramming visit after 12 months1 6.0 rsonal use only 7 6.0 Visits per year, per Patient Average Visits2 with Standard SCS2 6 5 4 3.1 Average Visits <1 visit per year after the first 12 month
Slide 6: EVA Automated Programming System Changes the Game
EVATM Automated Programming System Changes the Game Deep Data Analytics and Automation for Personalised Therapy rsonal use only 92% 96% Pain responder Patient (≥50% Pain relief)1 = 97% satisfaction1 000 67% Of Patients felt a Pain high responder Analysethe Find the DeterminePersonalised sense of con
Slide 7: Q1 FY27 Quarterly Activity Report
Q1 FY27 Quarterly Activity Report ASX announcement highlights Q1 Q1 Growth ▪ Global revenue of US$23.1 million, +26% vs prior corresponding FY27 FY26 vs. PCP rsonal use only period (pcp), reflecting continued commercial momentum. US Revenue ($m) 17.4 12.9 34% ▪ Quarterly US patient implants of 838,
Slide 8: Q1 FY27 Quarterly Activity Report: Revenue and select US commercial metrics
Q1 FY27 Quarterly Activity Report Revenue and select US commercial metrics QUARTERLY REVENUE TREND (US$M) 1 QUARTERLY US COMMERCIAL METRICS 1 rsonal use only 900.0 ASX IPO $27.0M US Implanted Patients US Avg Qtrly Active Physicians 838 800.0 US Int'l 769 $23.8M 700.0 $23.1M 8.5 3 3 695 $21.0M 670 60
Slide 9: FY27 Guidance Reaffirmed
FY27 Guidance Reaffirmed Full-year guidance ranges unchanged from the year-end release rsonal use only FY27 GUIDANCE Q1 COMMERCIAL PROGRESS US$ millions, except margin FY27 range Change Y/Y +55% US patient implants 838 in Q1 FY27 Revenue $113 – $122 +25% – 35% +47% US active physicians 374 quarterly
Slide 10: Strong Market Adoption with Key Future Growth Drivers
1 Strong Market Adoption with Key Future Growth Drivers Evoke® System gaining market share with positive momentum since launch rsonal use only REVENUE PROFILE (US$M) 1 KEY GROWTH DRIVERS Growth in key metrics – well positioned to continue expansion into FY27 and beyond +30% CAGR $113-$122 Expand int
Slide 11: Paddle Lead: Entering the Orthopedic / Neurosurgeon Market
Expand into New Expand Within Launch Enter New Territories Existing Physicians New Products Channels Paddle Lead: Entering the Orthopedic / Neurosurgeon Market O RT H O / N E U RO S U RG E O N S : 3 0 % O F U.S . M A R K E T 2 PADDLE LAUNCH rsonal use only Competitive Early stage of LAUNCH UNDERWAY
Slide 12: Why Saluda Is Different
Why Saluda Is Different Solving structural barriers that have limited SCS adoption and profitability THE TWO BIGGEST PROBLEMS IN SCS THE SALUDA ANSWER rsonal use only 1 Durability of outcomes Outcomes that hold up over time Effectiveness fades — driving reprogramming & attrition 83% 90% ZERO RESPOND
Slide 13: Everything Changes. This Changes Everything.
rsonal use only EVERYTHING CHANGES. THIS CHANGES EVERYTHING. Therapy as Dynamic as Life.